Literature DB >> 9431988

The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans.

J C Brown1, T Sasaki, W Göhring, Y Yamada, R Timpl.   

Abstract

Domain V of the major basement-membrane proteoglycan perlecan, a domain which consists of three laminin type G (LG) and four epidermal-growth-factor-like (EG) modules, was obtained in recombinant form by transfecting embryonic kidney cells with an episomal expression vector. A major 90-kDa fragment V was obtained together with fragments Va (74 kDa) and Vb (26 kDa) which were generated by endogenous proteolysis in front of the most C-terminal LG module. All three fragments bound to a heparin affinity column and could be displaced at a moderate (0.2 M) NaCl concentration. Rotary-shadowing electron microscopy demonstrated a three-globule structure for fragment V. Fragment V also showed a strong immunological cross-reaction with tissue-derived perlecan, indicating that it was folded into a native structure. A further, larger fragment, Vc, was apparently substituted with heparan sulphate and/or chondroitin sulphate chains and failed to bind to heparin. Fragment V but not fragment Vc promoted a distinct adhesion of several cell lines and this could be blocked by antibodies against the integrin beta1 chain. This domain may, however, represent only one of several cell-adhesive sites of perlecan. The recombinant perlecan fragment V bound in surface plasmon resonance assays to fibulin-2, laminin-nidogen complex, nidogen and two nidogen fragments. This indicated two different nidogen-binding epitopes on perlecan domain V with about a 10-fold difference in their affinities (Kd = 0.05-0.2 microM and about 2 microM). Perlecan domain V therefore seems to participate in the supramolecular assembly and cell connections of basement membranes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431988     DOI: 10.1111/j.1432-1033.1997.t01-1-00039.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  46 in total

1.  Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.

Authors:  J F Talts; Z Andac; W Göhring; A Brancaccio; R Timpl
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

Review 3.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

4.  Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

5.  Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.

Authors:  Muneaki Ishijima; Nobuharu Suzuki; Kentaro Hozumi; Tomoya Matsunobu; Keisuke Kosaki; Haruka Kaneko; John R Hassell; Eri Arikawa-Hirasawa; Yoshihiko Yamada
Journal:  Matrix Biol       Date:  2012-03-07       Impact factor: 11.583

Review 6.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

7.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

Review 8.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

9.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

10.  Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels.

Authors:  Holger Pflicke; Michael Sixt
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.